ABSTRACT
Objective To explore the expression of the nuclear factor -κB (NF-κB) regulating monocyte ehemoactracttive peptide -1 ( MCP-1) in asthma patients, and investigate the effect of seretide, budesonide and vento-lin. Methods 81 asthma patients were randomly divided into seretide therapy group and budesonide and ventolin therapy group. The NF-κB activation in PBMC and the plasma concentrations of MCP-1 were measured by ELISA. ventolin therapy group (1.70±0.39) ng/L of asthma patients were significantly higher than that control group (0.89±0.34) ng/L ( P<0.001 ) ; The plasma MCP-1 level in seretide therapy group ( 66.89±5.62 ) ng/L and in budesonide and ventolin therapy group (73.35±7.52 ) ng/L of asthma patients were also significantly higher than level of seretide therapy group in asthma patients were significantly lower than budesonide and ventolin therapy group (P <0.001 ). Conclusion NF-κB gene and its regulating protein MCP-1 may be involved in asthma. Glucocotios-teroid and beta2 agonists combination may prolong the process of asthma.